Abstract
Fibrosis is a pathological process of wound healing, characterized by excessive deposition of extracellular matrix (ECM) and chronic activation of fibroblasts, leading to organ scarring and a decline in function. Fibrogenesis is predominantly initiated by tissue injury and sustained inflammation, further driven by the complex interplay of growth factors, cytokines, metabolic alterations, and epigenetic reprogramming. Activated myofibroblasts and immune cells function as primary profibrotic mediators. The central molecular pathways implicated include TGF-β/SMAD signaling, non-canonical cascades such as RAS-ERK and PI3K-AKT-mTOR, and integrin-mediated mechanotransduction. These pathways collectively contribute to matrix disruption by upregulating α-SMA, collagen, lysyl oxidase, and tissue inhibitors of metalloproteinases (TIMPs). Alterations in noncoding RNAs and histone/DNA modifications stabilize genes responsible for pro-fibrotic pathways, whereas metabolic reprogramming sustains myofibblast activity. These mechanisms contribute to fibrosis in several autoimmune disorders, including rheumatoid arthritis, multiple sclerosis, Sjögren's disease, and Crohn's disease. In these conditions, persistent immune activation drives continuous crosstalk between immune cells and stromal fibroblasts, sustaining cytokine signaling and ECM remodeling. Current therapeutic approaches primarily aim to halt disease progression; however, achieving true reversal remains challenging. The significant morbidity and mortality associated with fibrotic diseases underscore the need for clinically validated biomarkers to guide effective combined therapeutic regimens capable of reversing established scarring. In this review, we explored emerging strategies that emphasize the integration of immune modulation, epigenetic reprogramming, and mechanobiological interventions to inhibit myofibroblast proliferation and facilitate matrix degradation and tissue regeneration.